Menu
You have to log in or sign up before you can proceed.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Fluor Completes Bayer’s First Global Cell Therapy Launch Facility in Berkeley, California


Fluor Corporation (NYSE: FLR) announced today that it has completed construction of Bayer’s first global Cell Therapy Launch Facility in Berkeley, California. Completion was celebrated October 10, 2023, at the new facility with local officials, dignitaries, Bayer employees and clients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231018153130/en/

Bayer's first global Cell Therapy Launch Facility was recently completed by Fluor Corporation. The new, state-of-the-art biopharmaceutical development and manufacturing facility will be used to produce cell therapies for neurological degenerative disorders, cardiovascular disease and other unmet medical needs. (Photo: Business Wire)

Bayer's first global Cell Therapy Launch Facility was recently completed by Fluor Corporation. The new, state-of-the-art biopharmaceutical development and manufacturing facility will be used to produce cell therapies for neurological degenerative disorders, cardiovascular disease and other unmet medical needs. (Photo: Business Wire)

“Fluor’s innovative plant layout and modularized construction approach allowed this facility to be built safely and with capital efficiency,” said Richard Meserole, president of Fluor’s Advanced Technologies & Life Sciences business line. “The project was phased to allow start-up activities to commence as needed to support production timeline.”

The new state-of-the-art biopharmaceutical development and manufacturing facility will be used to produce cell therapies for neurological degenerative disorders, cardiovascular disease and other unmet medical needs.

Fluor’s scope of work included the engineering, procurement, construction management, commissioning, qualification and validation for the facility.

Fluor also completed construction of Bayer’s state-of-the-art Single Use Technology biopharmaceutical manufacturing Cell Culture Technology Center (CCTC) in 2021. The CCTC supports Bayer’s teams producing multiple biologic therapies.

About Fluor Corporation

Fluor Corporation (NYSE: FLR) is building a better world by applying world-class expertise to solve its clients’ greatest challenges. Fluor’s 40,000 employees provide professional and technical solutions that deliver safe, well-executed, capital-efficient projects to clients around the world. Fluor had revenue of $13.7 billion in 2022 and is ranked 303 among the Fortune 500 companies. With headquarters in Irving, Texas, Fluor has provided engineering, procurement and construction services for more than 110 years. For more information, please visit www.fluor.com or follow Fluor on Twitter, LinkedIn, Facebook and YouTube.

#ATLS

View source version on businesswire.com: https://www.businesswire.com/news/home/20231018153130/en/

Fluor Corp. Stock

€44.38
1.070%
Fluor Corp. gained 1.070% today.
Fluor Corp. is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
However, we have a potential of -3.11% for Fluor Corp. as the target price of 43 € is below the current price of 44.38 €.
Like: 0
Share
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments